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Serratia Myositis  
in an Intravenous Drug User
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A b s t r A c t
Serratia marcescens is a well-known causative agent of hospital-acquired infections, 
especially in the intensive care unit (ICU), but can also cause community-acquired in-
fections. Infectious myositis due to Serratia is an extremely rare infection. We present 
a rare case of myositis due to Serratia marcescens in an intravenous drug user. To the 
best of our knowledge this is the first case of Serratia marcescens infectious myositis 
in an intravenous drug user. Our report not only reminds us that Serratia marcescens 
could be a pathogen in the community, but also highlights the fact that drug users 
are a special population with rare and unusual infections and as a result the clinician 
must have a high clinical suspicion and vigilance in order to diagnose and treat them.
I N t r O D U c t I O N
Serratia spp, particularly Serratia marcescens, have been recognized as a cause of a 
wide variety of hospital-acquired infections, especially in the intensive care unit (ICU). 
However, various studies have shown that a considerable percentage of Serratia spp 
infections are also community-acquired.1 Respiratory, urinary tract infections and 
keratitis/endophtalmitis are the most common, with meningitis, bacteremia, endo-
carditis, peritonitis, osteomyelitis and skin infections being occasionally reported.1 
Myositis due to Serratia is an extremely rare infection. To the best of our knowledge, 
only two documented cases of infectious myositis due to Serratia marcescens have been 
described in the literature.2,3 We present a case of myositis due to Serratia marcescens 
in an intravenous drug user.
c A s E  P r E s E N t A t I O N
A 38-year-old man presented to the emergency department with a 1-week history 
of pain in the left flank and thigh and fever with rigor during the preceding three 
days. There was no history of trauma, intense physical exercise or recent admission to 
a hospital. Five years earlier, hepatitis C had been diagnosed and the patient was an 
intravenous drug user of illicit drugs.
On examination, the patient was alert and oriented and appeared distressed. The 
temperature was 38oC, the blood pressure 110/70 mm Hg and the pulse rate 100 beats 
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per minute. He was unable to rise or walk because of the severe 
pain in his left flank that radiated to his left thigh. There was 
also pain during the active and passive movements of his left 
hip joint. There was no swelling, erythema or signs of soft tis-
sue infection. The remainder of the examination was normal.
Laboratory studies revealed a hematocrit of 39%, white 
blood cell count (WBC) at 17.190/mm3, including 90% neu-
trophils, platelet count 217.000/mm3, normal renal function, 
aspartate aminotransferase (SGOT) 40 U/L, alanine ami-
notransferase (SGPT) 49 U/L, creatine phosphokinase (CPK) 
340 U/L and C-reactive protein 17 mg/dL. Urine analysis was 
normal and human immunodeficiency virus (HIV) antibody 
was negative. Chest and abdomen radiography and abdomen 
ultrasound were normal.
Blood and urine specimens were taken for culture and he 
was started empirically on combined intravenous antibiotic 
regimen with piperacillin-tazobactam 4.5 g tid and daptomy-
cin 500 mg qd, while he was placed on intravenous fluids for 
hydration and was administered drugs for analgesia.
Eight hours later, computed tomography (CT) of the abdo-
men and pelvis after the administration of oral and intravenous 
contrast material showed diffuse swelling and enlargement 
of the left psoas muscle, without evidence of intramuscular 
abscess, findings typical of myositis of the left psoas (Fig. 1).
Within 24 hours, both sets of the blood cultures turned 
positive and Serratia marcescens was identified. Urine cul-
ture revealed no microorganism. Antimicrobial therapy was 
switched to intravenous ciprofloxacin 400 mg bid and intra-
venous ceftriaxone 1 g bid.
The fever subsided within 5 days after initiation of treat-
ment, with a marked clinical improvement. On the 8th hospital 
day, the patient was able to walk without support only with 
a mild pain in his left flank. He received intravenous antimi-
crobial therapy for 5 more days and was discharged on oral 
ciprofloxacin 500 mg bid for one month, but unfortunately 
he did not attend his scheduled outpatient visit in order to 
repeat a CT.
D I s c U s s I O N
We presented a case of Serratia marcescens myositis in an 
intravenous drug user patient successfully treated with anti-
microbials. Myositis refers to inflammation of the muscles and 
may be due to infectious and non-infectious etiologies. Infec-
tious myositis which leads to localized collections within the 
muscles is referred to as pyomyositis or tropical pyomyositis, 
as it is an endemic disease in tropical regions.4
By definition, infectious myositis is a primary bacterial 
infection which involves the occurrence of transient bactere-
mia with no obvious local or adjacent source of infection. It is 
common throughout the tropics and it was thought to be rare 
in temperate climates, but with the increasing prevalence of 
immunocompromised patients, it is becoming more widely 
recognized in temperate countries.4 Predisposing factors are 
trauma, immunosuppresion (HIV infection, diabetes mellitus), 
malignancy and intravenous drug abuse.
Infectious myositis presents in three stages.4 The invasive 
stage involves infection of the muscle, which causes the muscle 
to become edematous and painful, without a focal collection 
(myositis). At this stage the condition may be cured by appro-
priate antibiotic therapy alone, as in our case. The suppurative 
stage is characterized by formation of an abscess (pyomyositis) 
and the last stage involves the systemic spread of the infection, 
leading to septicemia and shock. Treatment in the latter stages 
requires surgical drainage as well as appropriate antibiotics.
CT and magnetic resonance imaging (MRI) are the best 
imaging techniques for early diagnosis of myositis. The dura-
tion of antimicrobial therapy depends on the extent of the 
muscle involvement, response to therapy and the immune 
status of the host, but in general, it must last at least three 
weeks. During the suppurative stage, surgical drainage should 
be initiated early and serves as the main component of therapy.
Staphylococcus aureus is the main causative pathogen, af-
fecting 90% of the patients in tropical areas and 60% to 70% of 
cases in temperate regions. Gram negative bacteria are clearly 
the exception, even in tropical areas.5 Serratia marcescens is 
an extremely rare cause of myositis. To the best of our knowl-
edge, only two documented cases of infectious myositis due 
to Serratia marcescens have been described in the literature.2,3
Serratia marcescens is a well-known causative agent of 
hospital-acquired infections.1 More than 200 cases of hospital 
epidemics due to Serratia marcescens bacteremia have been 
described since 1950, which are caused by contamination of 
blood products, indwelling catheters, medical devices but also 
FIgUrE 1. Diffuse swelling and enlargement of the left psoas 
muscle (white arrow), without evidence of intramuscular ab-
scess.
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of materials in the hospital environment such as disinfectants, 
soaps and taps, since Serratia marcescens thrives in moist en-
vironments. According to the European Center for Disease 
Prevention and Control (ECDC), in 2008 Serratia marcesens 
was the causative agent of the 2% of ICU-related bacteremia. 
Overall, in the international literature, 75%-90% of Serratia 
marcescens bacteremia cases are hospital-acquired.6,7
In the past, it was thought that Serratia marcescens may 
be a serious pathogen in intravenous drug users, because of 
cases of septic arthritis, osteomyelitis and endocarditis caused 
by Serratia marcescens in heroin addicts during the 1970s,8 
but there have not been many reports of Serratia marcescens 
infections in this patient population since then.
Although skin and soft tissue infections are common 
among intravenous drug users, infectious myositis is rather 
rare, probably due to relative resistance of the musculature to 
infection.4 Muscle trauma is necessary before experimentally 
induced bacteremia causes myositis in animals.9 However, in-
travenous drug abuse is recognized as an important risk factor 
for myositis, especially in HIV patients.5,9 The microorganism 
reaches skeletal muscles during transient bacteremia which is 
caused by direct intravenous injections of contaminated mate-
rial or by introduction of commensal flora into the bloodstream 
through injection.10,11 The latter pathogenetic mechanism 
seems to be more important, since S. aureus, which is known 
to colonize drug users,12 is the leading cause of myositis in 
this population.
Our case describes the first documented case of infectious 
myositis due to Serratia marcesens in a drug user. The two 
other cases of Serratia marcescens myositis were in immuno-
compromised patients.2,3 Why Serratia marcescens myositis is 
so rare among intravenous drug users? Serratia marcescens is 
not a member of commensal skin flora in the community. Skin 
colonization with Serratia marcescens is exclusively hospital-
acquired, usually in elderly patients with previous antibiotic 
exposure. Therefore, the introduction of commensal flora into 
the bloodstream, which is the main pathogenetic mechanism of 
bacteremia in drug users, does not occur in the case of Serratia 
marcescens. Moreover, it is known that during the last decades, 
intravenous drug users can easily obtain sterile paraphernalia 
by hospitals, pharmacies or community programs, contrary to 
the 1970s, when sharing of syringes and the use of tap water was 
the rule.13 Probably that is the reason why Serratia marcescens 
infections are not so common today among drug users, as it 
would be expected. It is known -by the hospital outbreaks of 
Serratia marcescens bacteremia- that common use and pro-
longed exposure of moist devices in the environment are the 
ideal conditions for Serratia growth.1,8 Τhe intrinsic resistance 
of skeletal muscle to bacterial infection explains the rarity of 
myositis cases due to Serratia marcescens in drug users.
In conclusion, infectious myositis was thought to be a rare 
disease in temperate climates, but its occurrence is increasing 
during the recent years. To the best of our knowledge this is 
the first case of Serratia marcescens infectious myositis in an 
injection drug user. This case, not only reminds us that Ser-
ratia marcescens could be a pathogen in the community, but 
also highlights the fact that drug users is a special population 
with rare and unusual infections and as a result the clinician 
must have a high clinical suspicion and vigilance in order to 
diagnose and treat them.
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